Tate S S, Sweet R, McDowell F H, Meister A
Proc Natl Acad Sci U S A. 1971 Sep;68(9):2121-3. doi: 10.1073/pnas.68.9.2121.
Human erythrocytes have been found to contain appreciable amounts of DOPA decarboxylase (EC 4.1.1.26) activity. The enzyme activity in erythrocytes from patients with Parkinson's disease who were treated with DOPA was significantly lower than that of untreated patients and of normal individuals. Administration of the drug to mice led to a marked decrease of DOPA decarboxylase in liver and kidney, but not of the brain enzyme. The findings thus indicate that administration of DOPA leads to a decrease in peripheral DOPA decarboxylase, an effect that is expected to be of benefit in DOPA therapy of patients with Parkinson's disease. Peripheral DOPA decarboxylase concentration also decreases in mice after short periods of fasting; the findings suggest that the peripheral enzyme activities may be affected by various nutritional and perhaps hormonal influences, which may be partially responsible for the observed fluctuations in the motor abilities of Parkinsonian patients receiving constant doses of the drug. Study of DOPA decarboxylase activity in erythrocytes may be useful in following changes in patients receiving DOPA therapy and may also be of general interest and value in investigations of catecholamine metabolism in man.
已发现人类红细胞含有相当数量的多巴脱羧酶（EC 4.1.1.26）活性。接受多巴治疗的帕金森病患者红细胞中的酶活性显著低于未治疗患者和正常个体。给小鼠服用该药物导致肝脏和肾脏中的多巴脱羧酶显著减少，但脑酶未减少。因此，这些发现表明服用多巴会导致外周多巴脱羧酶减少，这一效应预计对帕金森病患者的多巴治疗有益。短期禁食后小鼠外周多巴脱羧酶浓度也会降低；这些发现表明外周酶活性可能受到各种营养因素以及可能的激素影响，这可能部分解释了接受固定剂量药物治疗的帕金森病患者运动能力出现的波动。研究红细胞中的多巴脱羧酶活性可能有助于跟踪接受多巴治疗患者的变化，并且在人类儿茶酚胺代谢研究中也可能具有普遍的意义和价值。
